{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:25:14Z","timestamp":1793064314444,"version":"4.5.0"},"reference-count":352,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004595","name":"Universiti Sains Malaysia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003200","name":"Ministry of Science Technology and Innovation","doi-asserted-by":"publisher","award":["FRGS\/1\/2019\/SKK08\/USM\/01\/2"],"award-info":[{"award-number":["FRGS\/1\/2019\/SKK08\/USM\/01\/2"]}],"id":[{"id":"10.13039\/501100003200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bcp.2026.117929","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T16:03:57Z","timestamp":1774713837000},"page":"117929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"P1","title":["Novel targeted therapies and immunological strategies for breast cancer treatment"],"prefix":"10.1016","volume":"250","author":[{"given":"Ali","family":"Mussa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahasin","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Talib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iletou","family":"Ehinnou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bragoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Hajissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor Fatmawati","family":"Mokhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohimah","family":"Mohamud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.I.","family":"Al-Hatamleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosline","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2026.117929_b0010","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-481154","article-title":"New treatment approaches for triple-negative breast cancer","volume":"45","author":"Riaz","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.bcp.2026.117929_b0015","first-page":"11","article-title":"Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing","volume":"8","author":"Larose","year":"2025","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41523-022-00411-3","article-title":"PARP inhibition in breast cancer: progress made and future hopes","volume":"8","author":"Tung","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b0025","first-page":"p","article-title":"CDK4\/6 Inhibitors: Game Changers in the Management of Hormone Receptor-Positive Advanced Breast Cancer?","volume":"32","author":"Shah","year":"2018","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.bcp.2026.117929_b0030","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s12276-025-01395-3","article-title":"Targeting CDK4\/6 in breast cancer","volume":"57","author":"Shanabag","year":"2025","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.117929_b0035","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2326-6066.CIR-20-0586","article-title":"Hallmarks of Resistance to Immune-Checkpoint Inhibitors","volume":"10","author":"Karasarides","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.117929_b0045","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00280-013-2121-1","article-title":"PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types","volume":"71","author":"Britten","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117929_b0050","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jconrel.2022.07.036","article-title":"Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches","volume":"349","author":"Davodabadi","year":"2022","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.bcp.2026.117929_b0055","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/978-3-031-70875-6_21","article-title":"Clinical Implications of Breast cancer intrinsic subtypes","volume":"1464","author":"Rios-Hoyo","year":"2025","journal-title":"Adv. Exp. Med. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2026.117929_b0065","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0070","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0075","doi-asserted-by":"crossref","unstructured":"Curigliano, G., X. Hu, R.A. Dent, et al. Trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). Journal of Clinical Oncology, 2024. 42(17_suppl): p. LBA1000-LBA1000. doi:10.1200\/JCO.2024.42.17_suppl.LBA1000.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000"},{"key":"10.1016\/j.bcp.2026.117929_b0080","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0085","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.117929_b0090","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s12282-024-01603-4","article-title":"Neoadjuvant talazoparib in patients with germline BRCA1\/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status","volume":"31","author":"Telli","year":"2024","journal-title":"Breast Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2026.117929_b0095","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.bcp.2026.117929_b0100","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic Triple-Negative breast Cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.bcp.2026.117929_b0110","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.bcp.2026.117929_b0115","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"28","key":"10.1016\/j.bcp.2026.117929_b0120","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117929_b0125","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41588-022-01041-y","article-title":"Breast tumor microenvironment structures are associated with genomic features and clinical outcome","volume":"54","author":"Danenberg","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2026.117929_b0130","doi-asserted-by":"crossref","unstructured":"Li, J.J., J.Y. Tsang., G.M. Tse, Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment. Cancers (Basel), 2021. 13(16): p. doi:10.3390\/cancers13164233.","DOI":"10.3390\/cancers13164233"},{"issue":"3","key":"10.1016\/j.bcp.2026.117929_b0135","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bcp.2026.117929_b0140","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1210\/endrev\/bnaf014","article-title":"The Roles of Natural Killer Cells in Breast Cancer Pathobiology and Their Regulation by Estrogens","volume":"46","author":"Byemerwa","year":"2025","journal-title":"Endocr. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2026.117929_b0145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/bcr2912","article-title":"The microenvironment in breast cancer progression: biology and implications for treatment","volume":"13","author":"Place","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b0150","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.semcancer.2019.07.028","article-title":"Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer","volume":"60","author":"Hill","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2026.117929_b0155","doi-asserted-by":"crossref","unstructured":"Walter, S.G., S. Scheidt, R. Ni\u00dfler, et al. In-Depth Characterization of Stromal Cells within the Tumor Microenvironment Yields Novel Therapeutic Targets. Cancers (Basel), 2021. 13(6): p. doi:10.3390\/cancers13061466.","DOI":"10.3390\/cancers13061466"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0160","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s13046-024-03218-1","article-title":"Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer","volume":"43","author":"Mussa","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b0165","doi-asserted-by":"crossref","unstructured":"Hu, Y., J. Gao, M. Wang, et al. Potential prospect of CDK4\/6 inhibitors in triple-negative breast cancer. Cancer Manag Res, 2021. 13: p. doi:10.2147\/CMAR.S310649.","DOI":"10.2147\/CMAR.S310649"},{"issue":"10","key":"10.1016\/j.bcp.2026.117929_b0170","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/2159-8290.CD-20-1540","article-title":"Inhibition of CDK4\/6 Promotes CD8 T-cell Memory Formation","volume":"11","author":"Heckler","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.117929_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104010","article-title":"Immune effects of CDK4\/6 inhibitors in patients with HR+\/HER2\u2212 metastatic breast cancer: Relief from immunosuppression is associated with clinical response","volume":"79","author":"Scirocchi","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2026.117929_b0180","doi-asserted-by":"crossref","unstructured":"Lappano, R., L.A. Todd, M. Stanic, et al. Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment. Cancers (Basel), 2022. 14(3): p. doi:10.3390\/cancers14030539.","DOI":"10.3390\/cancers14030539"},{"issue":"9","key":"10.1016\/j.bcp.2026.117929_b0185","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bcp.2026.117929_b0190","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/cas.16443","article-title":"Targeting cancer-associated fibroblasts: eliminate or reprogram?","volume":"116","author":"Yamazaki","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2026.117929_b0195","doi-asserted-by":"crossref","unstructured":"Sitia, L., A. Bonizzi, S. Mazzucchelli, et al. Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax. Cells, 2021. 10(2): p. doi:10.3390\/cells10020328.","DOI":"10.3390\/cells10020328"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0200","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.117929_b0205","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bcp.2026.117929_b0210","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117929_b0215","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression \u2014 implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0220","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx440.010","article-title":"LBA17 - Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic solid tumors","volume":"28","author":"Yamamoto","year":"2017","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117929_b0225","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0230","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1331355","article-title":"Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours","volume":"14","author":"Bigos","year":"2024","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117929_b0235","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamaoncol.2024.6872","article-title":"Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial","volume":"11","author":"Dieci","year":"2025","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117929_b0240","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.bcp.2026.117929_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.01.072","article-title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study","volume":"31","author":"Schmid","year":"2020","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117929_b0250","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2026.117929_b0255","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-3507","article-title":"Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1\/L1 blockade in metastatic triple-negative breast cancer","volume":"26","author":"Barroso-Sousa","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0260","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41523-022-00490-2","article-title":"Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer","volume":"8","author":"Vidula","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2026.117929_b0265","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0270","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-015-0070-4","article-title":"Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma","volume":"3","author":"Postow","year":"2015","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0275","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-013-2618-7","article-title":"Myeloid-derived suppressor cells in breast cancer","volume":"140","author":"Markowitz","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2026.117929_b0280","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2026.117929_b0285","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/cac2.12291","article-title":"Cancer-associated fibroblasts in breast cancer: Challenges and opportunities","volume":"42","author":"Hu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.bcp.2026.117929_b0290","article-title":"The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.117929_b0295","doi-asserted-by":"crossref","unstructured":"Raju, A., K. Thriveni., S.S. Bharatnur, Comprehensive Cytokine Gene Expression and Multiplex Analysis in Breast Cancer Patients: Insights Into Immune Profiles and Prognostic Factors' Association. Cureus, 2025. 17(6): p. e85288. doi:10.7759\/cureus.85288.","DOI":"10.7759\/cureus.85288"},{"issue":"9","key":"10.1016\/j.bcp.2026.117929_b0300","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2026.117929_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217918","article-title":"Circulating cytokine profiling and clustering identify biomarker predicting efficacy of ICI in combination with chemotherapy","volume":"631","author":"Xu","year":"2025","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.bcp.2026.117929_b0310","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-19-1954","article-title":"A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial","volume":"26","author":"Karn","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b0315","article-title":"Hypoxia in Breast Cancer-Scientific Translation to Therapeutic and Diagnostic Clinical Applications","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"issue":"supplement 2","key":"10.1016\/j.bcp.2026.117929_b0320","first-page":"570","article-title":"Clinical impact of 18F-FMISO PET in the distinction of intrinsic subtypes of breast cancer","volume":"57","author":"Yamane","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117194","article-title":"Transforming the \u201ccold\u201d tumors to \u201chot\u201d tumors: strategies for immune activation","volume":"241","author":"Kong","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117929_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106767","article-title":"Bifunctional HDAC and DNMT inhibitor induces viral mimicry activates the innate immune response in triple-negative breast cancer","volume":"197","author":"Fan","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"issue":"31","key":"10.1016\/j.bcp.2026.117929_b0335","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202502120","article-title":"Self-Promoting Targeted Delivery of Epigenetic Immunostimulants to Activate Breast Cancer Immunity via HDACs Downregulation and PD-L1 Upregulation","volume":"64","author":"Chen","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bcp.2026.117929_b0340","doi-asserted-by":"crossref","unstructured":"Kimmel, B.R., K. Arora, N.C. Chada, et al. Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody\u2013STING agonist conjugates. Nature Biomedical Engineering, 2025. 10.1038\/s41551-025-01400-0: p. doi:10.1038\/s41551-025-01400-0.","DOI":"10.1038\/s41551-025-01400-0"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0345","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12943-025-02380-0","article-title":"Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment","volume":"24","author":"Wang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0350","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12943-025-02366-y","article-title":"Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy","volume":"24","author":"Zeng","year":"2025","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.117929_b0355","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced\/Metastatic Solid Tumors or Lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b0360","doi-asserted-by":"crossref","unstructured":"Harrington, K.J., J. Brody, M. Ingham, et al. LBA15 - Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas. Annals of Oncology, 2018. 29: p. viii712. doi:doi:10.1093\/annonc\/mdy424.015.","DOI":"10.1093\/annonc\/mdy424.015"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0365","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41420-025-02682-8","article-title":"Empowering hypoxia to convert cold tumors into hot tumors for breast cancer immunotherapy","volume":"11","author":"Liu","year":"2025","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.bcp.2026.117929_b0370","doi-asserted-by":"crossref","unstructured":"Shin, M.H., E. Oh, Y. Kim, et al. Recent Advances in CAR-Based Solid Tumor Immunotherapy. Cells, 2023. 12(12): p. doi:10.3390\/cells12121606.","DOI":"10.3390\/cells12121606"},{"issue":"16_suppl","key":"10.1016\/j.bcp.2026.117929_b0375","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1200\/JCO.2024.42.16_suppl.3514","article-title":"Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0380","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b0385","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1016\/j.annonc.2020.08.639","article-title":"525O A phase I dose escalation study of PRS-343, a HER2\/4-1BB bispecific molecule, in patients with HER2-positive malignancies","volume":"31","author":"Ku","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0390","doi-asserted-by":"crossref","DOI":"10.1177\/15353702221089910","article-title":"Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1\/TGF\u03b2RII agent: Current status","volume":"247","author":"Gameiro","year":"2022","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.bcp.2026.117929_b0395","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS19-P3-09-06","article-title":"Abstract P3\u201309\u201306: bintrafusp alfa (M7824), a bifunctional fusion protein targeting trans-forming growth factor-\u03b2 and programmed death ligand 1, in advanced triple-negative breast cancer: Preliminary results from a phase 1 cohort","volume":"80","author":"Spira","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b0400","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.bcp.2026.117929_b0405","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1158\/1078-0432.CCR-24-3888","article-title":"Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial","volume":"31","author":"Liu","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b0410","doi-asserted-by":"crossref","unstructured":"Wu J et al. A phase Ib\/II study to assess the safety and efficacy of PM8002 (anti-PD-L1 x VEGF-A bispecific antibody) in combination with nab-paclitaxel for first line treatment of locally advanced or metastatic triple-negative breast cancer. 2023 SABCS abstract #PS08\u201306. p.","DOI":"10.1158\/1538-7445.SABCS23-PS08-06"},{"key":"10.1016\/j.bcp.2026.117929_b0415","article-title":"Bispecific antibodies for triple negative breast cancer. Trends","volume":"7","author":"Dees","year":"2021","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2026.117929_b0420","article-title":"Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1\/CTLA-4 dual blocker in advanced solid tumors-A phase 1\/1b study","volume":"6","author":"Ma","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.117929_b0425","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-008-0185-0","article-title":"Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110","volume":"117","author":"Witthauer","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0430","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4161\/mabs.3.1.14193","article-title":"Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM\/CD3-bispecific BiTE antibody MT110","volume":"3","author":"Petsch","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.bcp.2026.117929_b0435","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.intimp.2017.10.008","article-title":"Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM\/CD3-bispecific BiTE antibody MT110 efficacy against IDO1(hi)breast cancer via enhancing immune cells activity","volume":"54","author":"Hong","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0440","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/0008-5472.CAN-07-2182","article-title":"Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3","volume":"68","author":"Amann","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0445","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12885-016-2449-0","article-title":"A phase I trial of the trifunctional anti Her2 \u00d7 anti CD3 antibody ertumaxomab in patients with advanced solid tumors","volume":"16","author":"Haense","year":"2016","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2026.117929_b0450","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1158\/1078-0432.CCR-05-2436","article-title":"Phase I Trial of the Trifunctional Anti-HER2 \u00d7 Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer","volume":"12","author":"Kiewe","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"16_suppl","key":"10.1016\/j.bcp.2026.117929_b0455","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2023.41.16_suppl.2508","article-title":"Phase 1\/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results","volume":"41","author":"Safran","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0460","doi-asserted-by":"crossref","unstructured":"Mark, C., J.S. Lee, X. Cui, et al. Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions. Int J Mol Sci, 2023. 24(18): p. doi:10.3390\/ijms241813726.","DOI":"10.3390\/ijms241813726"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0465","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40164-025-00632-9","article-title":"Antibody-drug conjugates in breast cancer: current evidence and future directions","volume":"14","author":"Li","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bcp.2026.117929_b0475","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2023.04.516","article-title":"Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0480","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-GS03-12","article-title":"Abstract GS03-12: Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis","volume":"84","author":"Loibl","year":"2024","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117929_b0485","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study","volume":"35","author":"Perez","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, Pertuzumab, and chemotherapy versus trastuzumab emtansine plus Pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0495","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.00896","article-title":"Trastuzumab emtansine plus Pertuzumab versus taxane plus trastuzumab plus Pertuzumab after anthracycline for High-Risk human epidermal growth factor receptor 2-Positive early breast cancer: the phase III KAITLIN study","volume":"40","author":"Krop","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0500","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab Deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0505","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab Deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial","volume":"25","author":"Perez-Garcia","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.117929_b0515","first-page":"p","article-title":"Trastuzumab Deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","author":"Harbeck","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0520","doi-asserted-by":"crossref","unstructured":"Loibl, S., H. Park Yeon, Z. Shao, et al. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. New England Journal of Medicine. 0(0): p. doi:10.1056\/NEJMoa2514661.","DOI":"10.1056\/NEJMoa2514661"},{"key":"10.1016\/j.bcp.2026.117929_b0525","doi-asserted-by":"crossref","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA et al. Trastuzumab Deruxtecan after endocrine therapy in metastatic breast Cancer. N Engl J Med. 2024. p.","DOI":"10.1056\/NEJMoa2407086"},{"issue":"5","key":"10.1016\/j.bcp.2026.117929_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105082","article-title":"Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial","volume":"10","author":"Hu","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.bcp.2026.117929_b0535","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab Deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-Positive human epidermal growth factor receptor 2-Negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0540","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab Govitecan in hormone receptor-Positive\/Human epidermal growth factor receptor 2-Negative metastatic breast Cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab Govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.117929_b0550","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251320285","article-title":"Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials","volume":"17","author":"Gluz","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"10.1016\/j.bcp.2026.117929_b0555","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","article-title":"Sacituzumab govitecan in HR+HER2\u2212 metastatic breast cancer: the randomized phase 3 EVER-132-002 trial","volume":"30","author":"Xu","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0560","doi-asserted-by":"crossref","unstructured":"Bardia, A., H.S. Rugo, M.S. Sedrak, et al. Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer. JCO Oncol Pract, 2025. 10.1200\/op-24-00806: p. Op2400806. doi:10.1200\/op-24-00806.","DOI":"10.1200\/OP-24-00806"},{"key":"10.1016\/j.bcp.2026.117929_b0565","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.34424","article-title":"A phase IIb, single arm, multicenter trial of sacituzumab Govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","volume":"152","author":"Xu","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.11.018","article-title":"Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial","volume":"35","author":"Spring","year":"2024","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.bcp.2026.117929_b0575","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic HR+\/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.556","article-title":"379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): updated results from BEGONIA, a phase Ib\/II study","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0585","first-page":"p","article-title":"Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","author":"Khoury","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0590","first-page":"p","article-title":"Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","author":"Shatsky","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0595","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Dieras","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117929_b0605","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2026.117929_b0610","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0620","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-Targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b0625","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-hziy in refractory metastatic Triple-Negative breast Cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.117929_b0630","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.bcp.2026.117929_b0635","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.117929_b0640","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70291","article-title":"Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+\/HER2- Metastatic Breast Cancer Data From the Phase 3 TROPiCS-02 Trial","volume":"18","author":"Sathe","year":"2025","journal-title":"Clin. Transl. Sci."},{"issue":"21","key":"10.1016\/j.bcp.2026.117929_b0645","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1158\/1078-0432.CCR-25-1388","article-title":"FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer","volume":"31","author":"Royce","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b0650","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0655","unstructured":"Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ et al. Adjuvant trastuzumab emtansine versus Paclitaxel plus trastuzumab for stage I human epidermal growth factor receptor 2-Positive breast cancer: 5-Year results and correlative analyses from ATEMPT. J Clin Oncol. 2024:JCO2302170. p."},{"issue":"8","key":"10.1016\/j.bcp.2026.117929_b0660","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117929_b0665","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0670","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in previously treated HER2-Positive breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.117929_b0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab Deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0680","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab Deruxtecan: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2026.117929_b0685","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study","author":"Pistilli","year":"2025","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117929_b0690","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/OP.24.00242","article-title":"Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"21","author":"Alaklabi","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.bcp.2026.117929_b0695","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.117929_b0700","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2026.117929_b0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104241","article-title":"Antibody\u2013drug conjugates: prospects for the next generation","volume":"29","author":"Grairi","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"19","key":"10.1016\/j.bcp.2026.117929_b0710","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0715","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2026.117929_b0720","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00228-025-03915-6","article-title":"Economic evaluation of antibody-drug conjugates (ADCs) in patients with breast cancer: systematic review","volume":"81","author":"Rezaei","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0725","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","article-title":"Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"10.1016\/j.bcp.2026.117929_b0730","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0735","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41523-022-00471-5","article-title":"STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer","volume":"8","author":"Pantelidou","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.117929_b0740","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0745","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1002\/onco.13551","article-title":"FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer","volume":"26","author":"Arora","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0750","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41698-025-00837-5","article-title":"Examining patient-specific responses to PARP inhibitors in a novel, human induced pluripotent stem cell-based model of breast cancer","volume":"9","author":"Weddle","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0755","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0760","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-23-2513","article-title":"Phase II DORA study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer","volume":"30","author":"Tan","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103220","article-title":"198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: patient-reported outcomes from KEYLYNK-009","volume":"9","author":"Cussac","year":"2024","journal-title":"ESMO Open"},{"issue":"45","key":"10.1016\/j.bcp.2026.117929_b0770","doi-asserted-by":"crossref","first-page":"79175","DOI":"10.18632\/oncotarget.16577","article-title":"Phase I\/Ib study of olaparib and carboplatin in women with triple negative breast cancer","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.117929_b0775","article-title":"A phase I\/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes","volume":"109","author":"Yonemori","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b0780","article-title":"Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)","volume":"32(1),:49\u201357","author":"Fasching","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0785","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0790","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cpt.1103","article-title":"Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations","volume":"105","author":"Pilla Reddy","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0795","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1038\/s41467-025-59151-0","article-title":"Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II\/III trial","volume":"16","author":"Abraham","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117929_b0800","doi-asserted-by":"crossref","unstructured":"Hoy, S.M.1, Talazoparib: first global approval. Drugs, 2018. 78: p. doi:10.1007\/s40265-018-1026-z.","DOI":"10.1007\/s40265-018-1026-z"},{"key":"10.1016\/j.bcp.2026.117929_b0805","article-title":"Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1\/2 Mutations and Selected Sporadic Cancers","volume":"7","author":"Bono","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.117929_b0810","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-1891","article-title":"A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1\/2 Mutations (ABRAZO) Talazoparib in gBRCA1\/2-Mutated Advanced Breast Cancer","volume":"25","author":"Turner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b0815","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0493","article-title":"Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial","volume":"25","author":"Hurvitz","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.bcp.2026.117929_b0820","doi-asserted-by":"crossref","unstructured":"Litton, J.K., J.T. Beck, J.M. Jones, et al. Neoadjuvant talazoparib in patients with germline BRCA1\/2 (gBRCA1\/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study. Journal of Clinical Oncology. 39(15_suppl): p. 505-505. doi:10.1200\/JCO.2021.39.15_suppl.505.","DOI":"10.1200\/JCO.2021.39.15_suppl.505"},{"key":"10.1016\/j.bcp.2026.117929_b0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117929_b0830","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/annonc\/mdy257","article-title":"Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1\/2 mutation: patient-reported outcomes from the EMBRACA phase III trial","volume":"29","author":"Ettl","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0835","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40164-025-00667-y","article-title":"Immunotherapy in breast cancer: current landscape and emerging trends","volume":"14","author":"Ran","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0840","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2016.41","article-title":"Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer","volume":"114","author":"Drew","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2021.09.028","article-title":"Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1\/2 mutation","volume":"159","author":"Patsouris","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b0850","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2017.36","article-title":"A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours","volume":"116","author":"Wilson","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b0855","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-021-00240-w","article-title":"Cisplatin +\/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer","volume":"7","author":"Kalra","year":"2021","journal-title":"npj Breast Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2026.117929_b0860","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41416-024-02776-7","article-title":"PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers","volume":"131","author":"Kristeleit","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.117929_b0865","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/mco2.103","article-title":"Targeting DNA repair pathway in cancer: Mechanisms and clinical application","volume":"2","author":"Wang","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.bcp.2026.117929_b0870","article-title":"An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target","volume":"16","author":"Cortesi","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.bcp.2026.117929_b0875","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA","volume":"5","author":"Vinayak","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.bcp.2026.117929_b0880","article-title":"A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study)","volume":"76(4_Supplement):OT1\u201303\u201305","author":"Balmana","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b0885","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-0310","article-title":"Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG\/BIG5\u201313\/TESARO PR-30\u201350\u201310-C BRAVO Study","volume":"27","author":"Turner","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b0890","doi-asserted-by":"crossref","DOI":"10.1177\/15330338251350630","article-title":"Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Combination with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis","volume":"24","author":"Duan","year":"2025","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2026.117929_b0895","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.breast.2021.08.009","article-title":"Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review","volume":"60","author":"Sun","year":"2021","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0900","doi-asserted-by":"crossref","first-page":"450","DOI":"10.18632\/aging.202152","article-title":"Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis","volume":"13","author":"Wang","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.bcp.2026.117929_b0905","article-title":"BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0910","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105048","article-title":"Effectiveness and safety of PARP inhibitors in breast cancer: An umbrella review of systematic reviews and meta-analyses","volume":"217","author":"Tzang","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117929_b0915","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b0920","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b0925","first-page":"p","article-title":"First-in-Class CDK4\/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer","volume":"40","author":"McCain","year":"2015","journal-title":"T"},{"key":"10.1016\/j.bcp.2026.117929_b0930","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30642-2","article-title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","volume":"22","author":"Mayer","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0935","article-title":"Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4\/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced CancerPhase I, Dose-Escalation Trial of PD 0332991, 4-Week Cycle","volume":"8","author":"Flaherty","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2021.05.035","article-title":"Phase I\/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer","volume":"154","author":"Yuan","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b0945","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0950","volume":"42","author":"Mayer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105186","article-title":"Clinical efficacy of CDK4\/6 inhibitor plus endocrine therapy in HR-positive\/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials","volume":"105","author":"Li","year":"2024","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.bcp.2026.117929_b0960","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0965","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-0305","article-title":"Overall Survival with Palbociclib and Fulvestrant in Women with HR+\/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study","volume":"28","author":"Cristofanilli","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.bcp.2026.117929_b0970","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-20-0844","article-title":"Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial","volume":"26","author":"Ciruelos","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2026.117929_b0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105572","article-title":"Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial","volume":"10","author":"Pascual","year":"2025","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.bcp.2026.117929_b0980","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.bcp.2026.117929_b0985","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.20.03639","article-title":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial","volume":"39","author":"Loibl","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b0990","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bcp.2026.117929_b0995","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b1000","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13058-023-01701-9","article-title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2\u2212 advanced breast cancer receiving first-line ribociclib plus fulvestrant","volume":"25","author":"Neven","year":"2023","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1005","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117929_b1010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117929_b1015","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaoncol.2025.3700","article-title":"Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive\/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial","volume":"11","author":"Fasching","year":"2025","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117929_b1020","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105858","article-title":"Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival","volume":"10","author":"Crown","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.bcp.2026.117929_b1025","article-title":"Abemaciclib in combination with pembrolizumab for HR+, HER2\u2212 metastatic breast cancer: phase 1b study. NPJ","volume":"8","author":"Rugo","year":"2022","journal-title":"Breast Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2026.117929_b1030","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117929_b1035","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(20)30112-1","article-title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial","volume":"21","author":"Tolaney","year":"2020","journal-title":"Lancet Oncol."},{"issue":"34","key":"10.1016\/j.bcp.2026.117929_b1040","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117929_b1045","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"Rastogi","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.bcp.2026.117929_b1050","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41388-025-03378-0","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment","volume":"44","author":"Guo","year":"2025","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bcp.2026.117929_b1055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007126","article-title":"Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)","volume":"11","author":"Masuda","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b1060","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1038\/s41467-023-41955-7","article-title":"Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial","volume":"14","author":"Yan","year":"2023","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bcp.2026.117929_b1065","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","article-title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","volume":"27","author":"Xu","year":"2021","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.117929_b1070","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1075","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Z. Zhang, H. Chen, et al. Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4\/6 inhibitor) plus Aromatase Inhibitors in Operable HER2-Negative Luminal B Breast Cancer: A Prospective, Single-Center, Single-Arm, Phase II Trial (DANCER). MedComm (2020), 2025. 6(10): p. e70402. doi:10.1002\/mco2.70402.","DOI":"10.1002\/mco2.70402"},{"key":"10.1016\/j.bcp.2026.117929_b1080","doi-asserted-by":"crossref","unstructured":"Turner, N.C., E.L. Mayer, Y.H. Park, et al. Camizestrant + CDK4\/6 inhibitor (CDK4\/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+\/HER2\u2013 advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial. Journal of Clinical Oncology, 2025. 43(17_suppl): p. LBA4-LBA4. doi:10.1200\/JCO.2025.43.17_suppl.LBA4.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA4"},{"key":"10.1016\/j.bcp.2026.117929_b1085","doi-asserted-by":"crossref","unstructured":"Patnaik, A., D. Powell, A.H. Chourasia, et al. Abstract P4-08-17: First-in-human Phase 1 study of BTX-9341, a first-in-class, CDK4\/6 bifunctional degrader, as a monotherapy and in combination with fulvestrant in patients with advanced and\/or metastatic HR+\/HER2- breast cancer. Clinical Cancer Research, 2025. 31(12_Supplement): p. P4-08-17-P4-08-17. doi:10.1158\/1557-3265.SABCS24-P4-08-17.","DOI":"10.1158\/1557-3265.SABCS24-P4-08-17"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b1090","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1186\/s12885-025-14841-2","article-title":"Comparative efficacy and safety of CDK4\/6 inhibitors combined with endocrine therapy in HR+\/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2026.117929_b1095","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.7150\/jca.111362","article-title":"Impact of PIK3CA Mutations on the Clinical Benefits of CDK 4\/6 Inhibitors in HR+\/HER2- Advanced Breast Cancer: An Updated Pairwise and Network Meta-Analysis","volume":"16","author":"Wang","year":"2025","journal-title":"J. Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b1100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103063","article-title":"Endocrine-based strategies after CDK4\/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis","volume":"142","author":"Escudero","year":"2026","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2026.117929_b1105","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103535","article-title":"Efficacy and safety of systemic therapies following progression on CDK4\/6 inhibitors in patients with HR+\/HER2- metastatic breast cancer: a systematic review and network meta-analysis","volume":"89","author":"Buonaiuto","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bcp.2026.117929_b1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102861","article-title":"PI3K\/AKT\/mTOR inhibitors for hormone receptor-positive advanced breast cancer","volume":"132","author":"Hao","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2026.117929_b1115","doi-asserted-by":"crossref","unstructured":"Yuan, Y., H. Long, Z. Zhou, et al. PI3K-AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds. Biomolecules, 2023. 13(1): p. doi:10.3390\/biom13010093.","DOI":"10.3390\/biom13010093"},{"issue":"6","key":"10.1016\/j.bcp.2026.117929_b1120","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3577","article-title":"A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors","volume":"15","author":"Hudis","year":"2013","journal-title":"Breast Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.117929_b1125","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1158\/1078-0432.CCR-15-2365","article-title":"Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer","volume":"22","author":"Wisinski","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b1130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13058-019-1154-8","article-title":"Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and\/or PTEN loss\/PTEN mutation","volume":"21","author":"Xing","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1135","doi-asserted-by":"crossref","unstructured":"Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, et al. I-SPY 2 Consortium. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and\/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020;38(10):1059\u20131069. doi:10.1200\/JCO.19.01027. p.","DOI":"10.1200\/JCO.19.01027"},{"key":"10.1016\/j.bcp.2026.117929_b1140","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-16-0512","article-title":"A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors","volume":"7","author":"Saura","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.117929_b1145","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1150","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz177","article-title":"FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer","volume":"30","author":"Oliveira","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1155","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-021-06450-x","article-title":"Ipatasertib plus paclitaxel for PIK3CA\/AKT1\/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial","volume":"191","author":"Turner","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"issue":"19","key":"10.1016\/j.bcp.2026.117929_b1160","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1158\/1078-0432.CCR-24-0465","article-title":"Ipatasertib plus Paclitaxel for Patients with PIK3CA\/AKT1\/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial","volume":"30","author":"Dent","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1165","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-23-2084","article-title":"First-line ipatasertib, atezolizumab, and taxane triplet for metastatic triple-negative breast cancer: clinical and biomarker results","volume":"30","author":"Schmid","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1170","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-17-2260","article-title":"A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers","volume":"24","author":"Banerji","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1175","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-3953","article-title":"Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer","volume":"26","author":"Smyth","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1180","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-3053","article-title":"Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)","volume":"26","author":"Robertson","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1185","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz086","volume":"30","author":"Turner","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1190","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1195","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30817-4","article-title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial","volume":"21","author":"Jones","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1200","article-title":"Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial","author":"Schmid","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1205","doi-asserted-by":"crossref","unstructured":"Expert Consensus on the Clinical Application of PI3K\/AKT\/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition). Cancer Innov, 2025. 4(3): p. e70008. doi:10.1002\/cai2.70008.","DOI":"10.1002\/cai2.70008"},{"issue":"10","key":"10.1016\/j.bcp.2026.117929_b1210","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2174\/0109298673327425240815065221","article-title":"A Perspective of PI3K\/AKT\/mTOR Pathway Inhibitors to Overcome Drug-resistance in Breast Cancer Therapy","volume":"32","author":"Mandal","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117929_b1215","doi-asserted-by":"crossref","unstructured":"Maennling, A.E., M.K. Tur, M. Niebert, et al. Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. Cancers (Basel), 2019. 11(12): p. doi:10.3390\/cancers11121826.","DOI":"10.3390\/cancers11121826"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b1220","doi-asserted-by":"crossref","first-page":"16042","DOI":"10.1038\/sigtrans.2016.42","article-title":"The paradoxical functions of EGFR during breast cancer progression","volume":"2","author":"Ali","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.117929_b1225","article-title":"Can EGFR be a therapeutic target in breast cancer? Biochimica et Biophysica Acta (BBA) - Reviews on","volume":"1877","author":"Li","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b1230","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2024.101490","article-title":"EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: A critical review","volume":"7","author":"Mariam Raju","year":"2024","journal-title":"Results Chem."},{"key":"10.1016\/j.bcp.2026.117929_b1235","doi-asserted-by":"crossref","unstructured":"Smyth, E.C., N.C. Turner, C. Peckitt, et al. Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. Journal of Clinical Oncology. 33(15_suppl): p. 2508-2508. doi:10.1200\/jco.2015.33.15_suppl.2508.","DOI":"10.1200\/jco.2015.33.15_suppl.2508"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b1240","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1038\/s41467-022-30666-0","article-title":"Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer","volume":"13","author":"Coombes","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117929_b1245","doi-asserted-by":"crossref","unstructured":"Hyman, D.M., B. Tran, L. Paz-Ares, et al. Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. JCO Precision Oncology, 2019. 10.1200\/PO.19.00221(3): p. 1-13. doi:10.1200\/PO.19.00221.","DOI":"10.1200\/PO.19.00221"},{"issue":"4","key":"10.1016\/j.bcp.2026.117929_b1250","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-018-03765-3","article-title":"A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer","volume":"83","author":"Campone","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b1255","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13058-017-0807-8","article-title":"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(-) breast cancer that had progressed during or after prior endocrine therapy","volume":"19","author":"Musolino","year":"2017","journal-title":"Breast Cancer Res."},{"issue":"17","key":"10.1016\/j.bcp.2026.117929_b1260","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/1078-0432.CCR-24-3803","article-title":"Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+\/HER2- Metastatic Breast Cancer","volume":"31","author":"Gonzalez-Ericsson","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1265","doi-asserted-by":"crossref","unstructured":"Meng, Y., Y. Mu., J. Zhang1, 434TiP ALTER-BC-Ib-01: A prospective phase Ib study of anlotinib with trastuzumab deruxtecan (T-DXd) for HER2-low unresectable (u)\/metastatic (m) breast cancer (BC). Annals of Oncology, 2024. 35: p. S402. doi:10.1016\/j.annonc.2024.08.381.","DOI":"10.1016\/j.annonc.2024.08.381"},{"key":"10.1016\/j.bcp.2026.117929_b1270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102137","article-title":"MEK inhibitor resistance mechanisms and recent developments in combination trials","volume":"92","author":"Kun","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2026.117929_b1275","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.117929_b1280","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ctrv.2013.03.009","article-title":"Targeting the PI3K\/AKT\/mTOR and Raf\/MEK\/ERK pathways in the treatment of breast cancer","volume":"39","author":"Saini","year":"2013","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2026.117929_b1285","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","article-title":"Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer","volume":"149","author":"Duncan","year":"2012","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bcp.2026.117929_b1290","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.seminoncol.2015.09.023","article-title":"MEK1\/2 Inhibitors: Molecular Activity and Resistance Mechanisms","volume":"42","author":"Wu","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1295","doi-asserted-by":"crossref","unstructured":"Cheng, Y. and H. Tian1, Current Development Status of MEK Inhibitors. Molecules, 2017. 22(10): p. doi:10.3390\/molecules22101551.","DOI":"10.3390\/molecules22101551"},{"issue":"10","key":"10.1016\/j.bcp.2026.117929_b1300","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1039\/D3MD00145H","article-title":"MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives","volume":"14","author":"Ram","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bcp.2026.117929_b1305","doi-asserted-by":"crossref","unstructured":"Ramaswamy, B., E. Mrozek, M. Lustberg, et al. Abstract LB-216: NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancer. Cancer Research, 2016. 76(14_Supplement): p. LB-216-LB-216. doi:10.1158\/1538-7445.AM2016-LB-216.","DOI":"10.1158\/1538-7445.AM2016-LB-216"},{"issue":"4","key":"10.1016\/j.bcp.2026.117929_b1310","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-020-04038-8","article-title":"Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1\/MEK2 inhibitor trametinib in patients with solid tumors","volume":"85","author":"Tolcher","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b1315","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-024-07551-z","article-title":"Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795\/uprosertib in patients with metastatic triple negative breast cancer","volume":"210","author":"Prasath","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"issue":"10","key":"10.1016\/j.bcp.2026.117929_b1320","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ejca.2015.03.016","article-title":"Fulvestrant with or without selumetinib, a MEK 1\/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21\/08","volume":"51","author":"Zaman","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2026.117929_b1325","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.annonc.2021.01.065","article-title":"A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis","volume":"32","author":"Brufsky","year":"2021","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117929_b1330","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1158\/1078-0432.CCR-24-3001","article-title":"Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer","volume":"31","author":"Chumsri","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117929_b1335","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","article-title":"Angiogenesis in cancer","volume":"2","author":"Nishida","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b1340","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.117929_b1345","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.117929_b1350","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.seminoncol.2003.08.013","article-title":"A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer","volume":"30","author":"Cobleigh","year":"2003","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117929_b1355","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1360","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.bcp.2026.117929_b1365","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1370","doi-asserted-by":"crossref","unstructured":"Robert, N.J., V. Dieras, J. Glaspy, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl): p. 1005-1005. doi:10.1200\/jco.2009.27.15_suppl.1005.","DOI":"10.1200\/jco.2009.27.15_suppl.1005"},{"key":"10.1016\/j.bcp.2026.117929_b1375","doi-asserted-by":"crossref","unstructured":"Brufsky, A., R.R. Rivera, S.A. Hurvitz, et al. Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). Journal of Clinical Oncology. 28(15_suppl): p. 1021-1021. doi:10.1200\/jco.2010.28.15_suppl.1021.","DOI":"10.1200\/jco.2010.28.15_suppl.1021"},{"issue":"12","key":"10.1016\/j.bcp.2026.117929_b1380","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.21.01506","article-title":"CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1385","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2022.05.014","article-title":"Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)","volume":"171","author":"Ozaki","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.117929_b1390","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011314","article-title":"Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial","volume":"13","author":"Chen","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b1395","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-4313","article-title":"Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase II trial","volume":"28","author":"Chen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1400","article-title":"The overall survival analysis of FUTURE-C-PLUS: combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer\u2014an open-label, single-arm, phase 2 trial","volume":"41","author":"Chen","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.bcp.2026.117929_b1405","article-title":"Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117929_b1410","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000696","article-title":"Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial","volume":"8","author":"Liu","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b1415","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221118053","article-title":"Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial","volume":"14","author":"Yang","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.bcp.2026.117929_b1420","article-title":"A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer","volume":"26","author":"Wang","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.bcp.2026.117929_b1425","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103792","article-title":"Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy","volume":"78","author":"Ji","year":"2024","journal-title":"Breast"},{"issue":"9","key":"10.1016\/j.bcp.2026.117929_b1430","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.117929_b1435","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer. JAMA","volume":"6","author":"Nanda","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.bcp.2026.117929_b1440","article-title":"Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: results from the I-SPY 2 TRIAL","volume":"80","author":"Liu","year":"2020","journal-title":"Can Res"},{"issue":"5","key":"10.1016\/j.bcp.2026.117929_b1445","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2020.01.072","article-title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study","volume":"31","author":"Schmid","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1450","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-LBO1-01","article-title":"Abstract LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study","volume":"84","author":"Schmid","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1455","doi-asserted-by":"crossref","unstructured":"Schmid P, Cortes J, Dent R, (eds) (2024) LBA4: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: overall survival results from the phase III KEYNOTE-522 study. 2024 ESMO Congress; Barcelona, Spain. p.","DOI":"10.1016\/j.annonc.2024.08.2247"},{"key":"10.1016\/j.bcp.2026.117929_b1460","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.117929_b1465","article-title":"Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer. JAMA","volume":"10","author":"Sharma","year":"2024","journal-title":"Oncol"},{"key":"10.1016\/j.bcp.2026.117929_b1470","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 tria","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.117929_b1475","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1480","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1485","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1490","doi-asserted-by":"crossref","unstructured":"Iwase, T., K.R.M. Blenman, X. Li, et al. A novel immunomodulatory 27-gene signature to predict response to neoadjuvant immunochemotherapy for primary triple-negative breast cancer. Cancers, 2021. 13: p. doi:10.3390\/cancers13194839.","DOI":"10.3390\/cancers13194839"},{"key":"10.1016\/j.bcp.2026.117929_b1495","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.102","article-title":"Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): evaluation of immune subtyping in the response predictive subtypes (RPS)","volume":"41","author":"Wolf","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1500","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.007","article-title":"LBA13 Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial","volume":"33","author":"Nederlof","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1505","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.602","article-title":"Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial","volume":"40","author":"Loi","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1510","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.608","article-title":"Phase II study of neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant stage III triple negative breast cancer (TNBC): BCT1702\u2014survival results","volume":"42","author":"Loi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1515","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-GS01-03","article-title":"Abstract GS01-03: Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA\/IMpassion030 phase 3 trial","volume":"84","author":"Ignatiadis","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1520","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 Study","volume":"34","author":"Nanda","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1525","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1530","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1535","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.010","article-title":"KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)","volume":"30","author":"Cort\u00e9s","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1540","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10265","key":"10.1016\/j.bcp.2026.117929_b1545","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.117929_b1550","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer. JAMA","volume":"5","author":"Emens","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.bcp.2026.117929_b1555","article-title":"Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up. JAMA","volume":"5","author":"Adams","year":"2019","journal-title":"Oncol"},{"issue":"22","key":"10.1016\/j.bcp.2026.117929_b1560","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.117929_b1565","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1570","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001112","article-title":"Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials\u2014How to explain different results?","volume":"5","author":"Franzoi","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.bcp.2026.117929_b1575","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.04.001","article-title":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","volume":"35","author":"Dent","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1580","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PS16-02","article-title":"Abstract PS16-02: Efficacy and safety of first-line atezolizumab + bevacizumab + paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial","volume":"84","author":"Gion","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1585","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-2182","article-title":"A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual Anti\u2013CTLA-4 and Anti\u2013PD-1 blockade in rare tumors (DART, SWOG S1609)","volume":"28","author":"Adams","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1590","doi-asserted-by":"crossref","unstructured":"Santa-Maria, C.A., T. Kato, J.H. Park, et al. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget, 2018. 9: p. doi:10.18632\/oncotarget.24867.","DOI":"10.18632\/oncotarget.24867"},{"key":"10.1016\/j.bcp.2026.117929_b1595","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-GS01-05","article-title":"Abstract GS01-05: Pembrolizumab + olaparib vs pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy for locally recurrent inoperable or metastatic TNBC: randomized open-label phase 2 KEYLYNK-009 study","volume":"84","author":"Rugo","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1600","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03734-3","article-title":"Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial","author":"Gion","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117929_b1605","doi-asserted-by":"crossref","unstructured":"Mollavelioglu, B., E. Cetin Aktas, N. Cabioglu, et al. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer. World J Surg Oncol, 2022. 20(1): p. 349. doi:10.1186\/s12957-022-02810-z.","DOI":"10.1186\/s12957-022-02810-z"},{"key":"10.1016\/j.bcp.2026.117929_b1610","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101305","article-title":"Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor","volume":"42","author":"Ruffo","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.bcp.2026.117929_b1615","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-8-71","article-title":"Firstline chemo-immunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity","volume":"8","author":"Brignone","year":"2010","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2026.117929_b1620","volume":"81","author":"Wildiers","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1625","doi-asserted-by":"crossref","unstructured":"Forget, F., S. Morales Murillo, N.K. Ibrahim, et al. AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg\/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization. Journal of Clinical Oncology, 2024. 42(16_suppl): p. TPS1125-TPS1125. doi:10.1200\/JCO.2024.42.16_suppl.TPS1125.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1125"},{"issue":"2","key":"10.1016\/j.bcp.2026.117929_b1630","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003776","article-title":"Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525) \u00b1 anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies","volume":"10","author":"Sch\u00f6ffski","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b1635","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2290787","article-title":"A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies","volume":"13","author":"Lin","year":"2024","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b1640","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b1645","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-025-01670-w","article-title":"Cancer vaccines: current status and future directions","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2026.117929_b1650","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nm.2161","article-title":"An autoimmune-mediated strategy for prophylactic breast cancer vaccination","volume":"16","author":"Jaini","year":"2010","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.bcp.2026.117929_b1655","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/cncr.26574","article-title":"Clinical trial results of the HER-2\/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02","volume":"118","author":"Mittendorf","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2026.117929_b1660","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu211","article-title":"Final report of the phase I\/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients","volume":"25","author":"Mittendorf","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1665","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-2867","article-title":"Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial","volume":"25","author":"Mittendorf","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1670","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-2741","article-title":"Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab versus trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer","volume":"26","author":"Clifton","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"40","key":"10.1016\/j.bcp.2026.117929_b1675","doi-asserted-by":"crossref","first-page":"66192","DOI":"10.18632\/oncotarget.11751","article-title":"Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence","volume":"7","author":"Mittendorf","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bcp.2026.117929_b1680","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-020-05638-x","article-title":"Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence","volume":"181","author":"Brown","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2026.117929_b1685","doi-asserted-by":"crossref","unstructured":"Garcia-Alvarez, A., A. Papakonstantinou., M. Oliveira, Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. Cancers (Basel), 2021. 13(12): p. doi:10.3390\/cancers13122927.","DOI":"10.3390\/cancers13122927"},{"issue":"16","key":"10.1016\/j.bcp.2026.117929_b1690","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1158\/1078-0432.CCR-23-1107","article-title":"Keeping It in the Family: HER3 as a Target in Brain Metastases","volume":"29","author":"Kabraji","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117929_b1695","doi-asserted-by":"crossref","unstructured":"Bhandarkar, V., T. Dinter., S. Spranger1, Architects of immunity: How dendritic cells shape CD8+ T cell fate in cancer. Science Immunology. 10(103): p. eadf4726. doi:10.1126\/sciimmunol.adf4726.","DOI":"10.1126\/sciimmunol.adf4726"},{"key":"10.1016\/j.bcp.2026.117929_b1700","doi-asserted-by":"crossref","unstructured":"Heery, C., N. Ibrahim, R.A. Madan, et al. LBA14 - A Phase 2 Randomized Trial of Docetaxel Alone or in Combination with Therapeutic Cancer Vaccine, CEA-, MUC-1-Tricom. Annals of Oncology, 2012. 23: p. ixe6. doi:doi:10.1016\/S0923-7534(20)34312-X.","DOI":"10.1016\/S0923-7534(20)34312-X"},{"key":"10.1016\/j.bcp.2026.117929_b1705","doi-asserted-by":"crossref","unstructured":"Abelman, R.O., B. Wu, L.M. Spring, et al. Mechanisms of Resistance to Antibody-Drug Conjugates. Cancers (Basel), 2023. 15(4): p. doi:10.3390\/cancers15041278.","DOI":"10.3390\/cancers15041278"},{"issue":"4","key":"10.1016\/j.bcp.2026.117929_b1710","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2022.5184","article-title":"CDK4\/6 inhibitor resistance mechanisms and treatment strategies (Review)","volume":"50","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.117929_b1715","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11912-020-00917-8","article-title":"Sequencing endocrine therapy for metastatic breast cancer: what do we do after disease progression on a CDK4\/6 inhibitor?","volume":"22","author":"Xi","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.bcp.2026.117929_b1720","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/1078-0432.CCR-18-4044","article-title":"Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance","volume":"26","author":"Pearson","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2026.117929_b1725","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70404","article-title":"Breast cancer: molecular pathogenesis and targeted therapy","volume":"6","author":"Samad","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.bcp.2026.117929_b1730","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.117929_b1735","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1266450","article-title":"Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview","author":"Lan","year":"2023","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2026.117929_b1740","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.117929_b1745","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117929_b1750","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.bcp.2026.117929_b1755","article-title":"Improved Efficacy of Triple-Negative Breast Cancer Immunotherapy via Hydrogel-Based Co-Delivery of CAR-T Cells and Mitophagy Agonist","volume":"12","author":"Li","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.bcp.2026.117929_b1760","doi-asserted-by":"crossref","first-page":"44","DOI":"10.22203\/eCM.v052a04","article-title":"Generation of three-dimensional (3D) breast cancer bone metastasis model for drug testing","volume":"52","author":"Nasser","year":"2025","journal-title":"Eur. Cell. Mater."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:21:48Z","timestamp":1780676508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226002625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":352,"alternative-id":["S0006295226002625"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117929","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel targeted therapies and immunological strategies for breast cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117929"}}